1 The effect of metabolic traits on oral and oropharyngeal cancer

2 risk: a Mendelian randomization analysis

- 3
- 4 Mark Gormley, BDS^{* 1,2}, Tom Dudding, PhD², Steven J Thomas, PhD², Jessica Tyrrell, PhD³,
- 5 Andrew R Ness, PhD⁴, Miranda Pring, PhD², Danny Legge, PhD⁵, George Davey Smith, FRS¹,
- 6 Rebecca C Richmond, PhD¹, Emma E Vincent, PhD^{1,5§}, Caroline Bull, PhD^{1,5§}
- 7 ¹ MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol,
- 8 Bristol, UK.
- 9 ² Bristol Dental Hospital and School, University of Bristol, Bristol, UK.
- ³ University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.
- ⁴ University Hospitals Bristol and Weston NHS Foundation Trust National Institute for Health Research Bristol
- 12 Biomedical Research Centre, University of Bristol, Bristol, UK
- ⁵ Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
- 14 § Joint senior authors
- 15 * Corresponding author: <u>mark.gormley@bristol.ac.uk</u>
- 16
- 17
- 18
- 19

20 Abstract

21

22 Introduction

23	A recent World Health Organization report states that at least 40% of all cancer cases may
24	be preventable, with smoking, alcohol consumption and obesity identified as three of the
25	most important modifiable lifestyle factors. Established risk factors for head and neck
26	cancer include tobacco use, alcohol consumption and human papillomavirus infection.
27	Given the significant decline in smoking rates, particularly within developing countries,
28	other potentially modifiable risk factors warrant investigation. Obesity and related
29	metabolic disorders such as type 2 diabetes and hypertension have all been associated with
30	head and neck cancer risk in multiple observational studies. However, obesity has also been
31	correlated with other major head and neck cancer risk factors such as smoking, meaning
32	independent effects are difficult to establish. Furthermore, selection bias, confounding or
33	reverse causality may explain the findings from observational studies.
34	
35	Methods
36	To overcome the challenges of observational studies, we conducted two-sample Mendelian
37	randomization (inverse variance weighted (IVW) method) using genetic variants which were

- robustly associated with obesity, T2D and hypertension in genome-wide association studies
- 39 (GWAS). Outcome data was taken from the largest available GWAS of 6,034 oral and
- 40 oropharyngeal cases, with 6,585 controls.
- 41
- 42 Results

43	We found limited evidence of a causal effect of genetically proxied body mass index (OR
44	IVW 0.89, 95%Cl 0.72–1.09, p = 0.26 per 1 SD in BMI (4.81 kg/m2)) on combined oral and
45	oropharyngeal cancer risk. Similarly, there was limited evidence for genetically-proxied T2D
46	(OR IVW 0.92, 95%CI 0.84–1.01, p = 0.09 per 1-log unit higher odds of T2D), or related traits
47	including fasting glucose and insulin. Higher HbA1c resulted in a weak protective effect on
48	combined oral and oropharyngeal cancer risk (OR IVW 0.56, 95%Cl 0.32–1.00, p = 0.05 per
49	1-log-unit % higher HbA1c), which was not robust to sensitivity testing. Finally, there was
50	limited evidence for an effect of systolic blood pressure on combined oral and
51	oropharyngeal cancer risk (OR IVW 1.00, 95%Cl 0.97–1.03, p = 0.89 per 1 unit mmHg
52	increase). Smoking also appears to act as a mediator in the relationship between obesity
53	and HNC in instrument-risk factor analyses.
54	
55	Conclusion
55 56	Conclusion This analysis suggests the possibility that the effect of metabolic disorders may have been
56	This analysis suggests the possibility that the effect of metabolic disorders may have been
56 57	This analysis suggests the possibility that the effect of metabolic disorders may have been previously overestimated in observational studies. However, these cannot be directly
56 57 58	This analysis suggests the possibility that the effect of metabolic disorders may have been previously overestimated in observational studies. However, these cannot be directly
56 57 58 59	This analysis suggests the possibility that the effect of metabolic disorders may have been previously overestimated in observational studies. However, these cannot be directly
56 57 58 59 60	This analysis suggests the possibility that the effect of metabolic disorders may have been previously overestimated in observational studies. However, these cannot be directly
56 57 58 59 60 61 62	This analysis suggests the possibility that the effect of metabolic disorders may have been previously overestimated in observational studies. However, these cannot be directly
56 57 58 59 60 61 62 63	This analysis suggests the possibility that the effect of metabolic disorders may have been previously overestimated in observational studies. However, these cannot be directly
56 57 58 59 60 61 62	This analysis suggests the possibility that the effect of metabolic disorders may have been previously overestimated in observational studies. However, these cannot be directly

66 Introduction

67

68	Head and neck squamous cell carcinoma (HNC), which includes cancers of the oral cavity
69	and oropharynx is the 7 th most common cancer, accounting for more than 660,000 new
70	cases and 325,000 deaths annually worldwide ^{1,2} . Established risks include tobacco use,
71	alcohol consumption ³ and human papillomavirus (HPV) infection, mainly associated with
72	oropharyngeal cancer and thought to be sexually transmitted 4 . A recent World Health
73	Organization (WHO) report states that at least 40% of all cancer cases may be preventable,
74	with smoking, alcohol consumption and obesity identified as three of the most important
75	modifiable lifestyle factors 5 . Smoking behaviour is declining, particularly in developing
76	countries and it has been projected that obesity could even supersede smoking as the
77	primary driver of cancer in the coming decades ⁵ . Despite changes in smoking rates, the
78	incidence of HNC continues to rise and a changing aetiology has been proposed ^{6,7} .
79	Therefore, less established risks such as obesity and its related metabolic traits warrant
80	investigation in HNC. However, obesity has been correlated with other HNC risk factors such
81	as smoking 8 , alcohol 9 and educational attainment 10 , meaning independent effects are
82	difficult to establish.

83

Obesity is now considered to increase the risk of at least 13 different types of cancer including breast, colorectal, gastric and oesophageal ¹¹, but the effect on HNC risk remains unclear ⁵. Public health strategies have been unsuccessful in addressing the current obesity epidemic at the population level, which could result in more cancer cases in the years to come ¹². Obesity and related metabolic traits such as type 2 diabetes (T2D), hypertension and dyslipidaemia have all been associated with head and neck cancer in multiple


90	observational studies. In the largest pooled analysis, obesity defined by higher body mass
91	index (BMI) was associated with a protective effect for HNC in current smokers (hazard ratio
92	(HR)20.76, 95% confidence intervals (95%CI) 0.71–0.82, <i>p</i> 2<0.0001, per 52kg/m ²) and
93	conversely, a higher risk in never smokers (HR 1.15, 95%CI 1.06–1.24 per 512kg/m², p <
94	0.001) ¹³ . In the same study, a greater waist circumference (WC) (HR221.04, 95%Cl 1.03–
95	1.05 per 5@cm, <i>p</i> @< 0.001) and waist-to-hip ratio (WHR) (HR@1.07, 95%Cl 1.05–1.09 per 0.1
96	unit, $p < 0.001$) were associated with increased HNC risk, which did not vary by smoking
97	status ¹³ . However, more recent cohort studies have failed to show a clear association
98	between BMI and HNC ¹⁴⁻¹⁸ . A meta-analysis of observational studies investigating T2D with
99	oral and oropharyngeal subsites, showed an increased risk ratio (RR) of 1.15, 95%CI 1.02–
100	1.29, <i>P heterogeneity</i> = 0.277 ¹⁹ , a result which is consistent with more recent independent
101	cohorts ^{14,20-22} . Hypertension (defined as a systolic blood pressure (SBP) > 130 mmHg or
102	diastolic blood pressure (DBP) > 85 mmHg), has been correlated with head and neck cancer
103	risk across multiple studies ²¹⁻²⁵ . Nonetheless, selection bias, confounding, or reverse
104	causation may explain the findings from these studies.
105	
106	Mendelian randomization (MR) is an analytical approach which attempts to overcome the
107	challenges of conventional epidemiological studies. The method uses germline genetic
108	single nucleotide polymorphisms (SNPs), which are randomly assorted during meiosis (and
109	fixed at conception), to estimate the causal effects of exposures on disease outcomes ²⁶⁻²⁸ .
110	Using MR, we recently found limited evidence for a role of circulating lipid traits in oral and
111	oropharyngeal cancer risk ²⁹ , however other metabolic traits remain untested in an MR

- 112 framework. Here, we employ a two-sample MR approach, integrating summary-level
- 113 genetic data from the largest available GWAS for metabolic traits, including obesity

114	measures (BMI, WC, WHR), glycaemic traits (T2D, glycated haemoglobin (HbA $_{1c}$), fasting
115	glucose (FG), fasting insulin (FI)), and blood pressure (SBP, DBP) to evaluate their causal
116	effect on oral and oropharyngeal cancer risk. Given the potential correlation of metabolic
117	traits and established HNC risk factors, further evaluation of instrument-risk factor effects
118	including smoking, alcohol, risk tolerance (as a proxy for sexual behaviour), and educational
119	attainment was carried out using MR.
120	
121	Methods
122	
123	Two-sample MR was performed using published summary-level data from the largest

124 available GWAS for each metabolic trait. MR makes three key assumptions, as described in

- 125 **Fig. 1**^{26,27}.
- 126



127

128 Figure 1. Directed acyclic graph (DAG) depicting Mendelian randomization applied to this

129 study

1	3	n
_	. –	<u> </u>

- 131 Genetic variants (G) act as proxies or instruments to investigate if an exposure (X), is associated with a trait
- e.g., body mass index or disease outcome (Y) e.g., oral/oropharyngeal cancer. Causal inference can be made
- 133 between X and Y if the following conditions are upheld:
- 134 (1) G is a valid instrument, reliably associated with X ('relevance');
- 135 (2) no measured (C) or unmeasured (U) confounding of the association between G and the Y
- 136 ('exchangeability');
- (3) there is no independent association of G with Y, except through X ('exclusion restriction principle').
- 138

139 Exposure summary statistics for metabolic traits

140

141	To instrument metabolic traits, we selected genetic variants associated ($p < 5 \times 10^{-8}$) with
142	traits of interest identified by previously conducted GWAS (Supplementary Data 1).
143	Clumping was performed to ensure single nucleotide polymorphisms (SNPs) in each
144	instrument were independent (linkage disequilibrium R ² < 0.001). Following clumping,
145	genetic instruments were comprised of: 312 SNPs for BMI, from a GWAS meta-analysis of
146	806,834 individuals of European ancestry, including the Genetic Investigation
147	of ANthropometric Traits (GIANT) consortium and UK Biobank $^{ m 30}$; 45 SNPs for WC, extracted
148	from the same GWAS ³⁰ ; 209 SNPs for WHR extracted from a GWAS meta-analysis describing
149	224,459 individuals of mainly European ancestry 31 ; 275 SNPs for T2D from the DIAMANTE
150	(DIAbetes Meta-ANalysis of Trans-Ethnic association studies) consortium of 228,499 cases
151	and 1,178,783 controls ³² ; 33 SNPs for FG and 18 SNPs for FI, obtained from a GWAS
152	published by the MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits) Consortium
153	(N = 151,188 and 105,056 individuals, respectively) 33 ; 58 SNPs for HbA _{1c} , taken from a
154	meta-analyses of 159,940 individuals from 82 cohorts of European, African, East Asian, and

155	South Asian ancestry 34 ; Finally, 105 and 78 SNPs for SBP and DBP, respectively, were
156	extracted from a GWAS meta-analysis of over 1 million participants in UK Biobank and the
157	International Consortium of Blood Pressure Genome Wide Association Studies (ICBP) $^{ m 35}$
158	(Supplementary Data 1).
159	
160	Outcome summary statistics for oral and oropharyngeal cancer
161	
162	We estimated the effects of metabolic traits on risk of oral and oropharyngeal cancer by
163	extracting exposure SNPs (Supplementary Data 1) from the largest available GWAS
164	performed on 6,034 cases and 6,585 controls from 12 studies which were part of the
165	Genetic Associations and Mechanisms in Oncology (GAME-ON) Network ³⁶ . Full details of
166	the included studies, as well as the genotyping and imputation performed, have been
167	described previously ^{36, 37} . In brief, the study population included participants from Europe
168	(45.3%), North America (43.9%) and South America (10.8%). Cancer cases comprised the
169	following the International Classification of Diseases (ICD) codes: oral cavity (C02.0-C02.9,
170	C03.0-C03.9, C04.0-C04.9, C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9),
171	hypopharynx (C13.0-C13.9), overlapping (C14 and combination of other sites) and 25 cases
172	with unknown ICD code (other). A total of 954 individuals with cancers of hypopharynx,
173	unknown code or overlapping cancers were excluded. Genomic DNA isolated from blood or
174	buccal cells was genotyped at the Center for Inherited Disease Research (CIDR) using an
175	Illumina OncoArray, custom designed for cancer studies by the OncoArray Consortium ³⁸ .
176	Principle components analysis was performed using approximately 10,000 common markers
177	in low LD ($r^2 < 0.004$), minor allele frequency (MAF) > 0.05 and 139 population outliers were
178	removed.

1	7	9
---	---	---

180	Given the differential association of potential risk factors at each subsite (i.e. smoking,
181	alcohol and HPV infection) ⁶ , we performed stratified MR analyses for oral and
182	oropharyngeal cancer to evaluate potential heterogeneity in effects. For this, we used
183	GWAS summary data on a subset of 2,990 oral and 2,641 oropharyngeal cases and the 6,585
184	common controls in the GAME-ON GWAS ³⁶ .
185	
186	Statistical analysis
187	
188	Two-sample MR was conducted using the "TwoSampleMR" package in R (version 3.5.3), by
189	integrating SNP associations for each metabolic trait (exposure, sample 1) with those for
190	oral and oropharyngeal cancer in GAME-ON (outcome, sample 2). We only used genetic
191	variants reaching GWAS significance ($p < 5 \times 10^{-8}$). The nearest gene was identified using
192	SNPsnap and a distance of +/- 500 kb ³⁹ . Firstly, metabolic trait-associated SNPs were
193	extracted from oral and oropharyngeal cancer summary statistics. Exposure and outcome
194	summary statistics were harmonised using the "harmonise_data" function of the
195	TwoSampleMR package so that variant effect estimates corresponded to the same allele.
196	Palindromic SNPs were identified and corrected using allele frequencies where possible
197	(alleles were aligned when minor allele frequencies were < 0.3, or were otherwise
198	excluded). For each SNP in each exposure, individual MR effect-estimates were calculated
199	using the Wald method (SNP-outcome beta/SNP-exposure beta) ⁴⁰ . Multiple SNPs were then
200	combined into multi-allelic instruments using random-effects inverse-variance weighted
201	(IVW) meta-analysis.

202

203	IVW estimates may be vulnerable to bias if genetic instruments are invalid and are only
204	unbiased in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced
205	⁴¹ . We therefore performed additional sensitivity analyses to evaluate the potential for
206	unbalanced horizontal pleiotropy using weighted median 42 , weighted mode 43 and MR-
207	Egger ⁴⁴ methods which are described in detail elsewhere ⁴⁵ . In short, the weighted median
208	stipulates that at least 50% of the weight in the analysis stems from valid instruments.
209	Weighted mode returns an unbiased estimate of the causal effect if the cluster with the
210	largest weighted number of SNPs for the weighted model are all valid instruments.
211	Instruments are weighted by the inverse variance of the SNP-outcome association. ⁴³
212	
213	Finally, MR-Egger provides reliable effect estimates even if variants are invalid and the
214	Instrument Strength Independent of Direct Effect (InSIDE) assumption is violated 44 . The
215	InSIDE assumption states that the association between genetic instrument and exposure
216	should not be correlated with an independent path from instrument to the outcome. In the
217	presence of unbalanced pleiotropy when the InSIDE assumption is violated, then the MR-
218	Egger result may be biased 45 . Gene variants must be valid instruments and where there was
219	evidence of violation of the negligible measurement error (NOME) assumption 46 , this was
220	assessed using the I^2 statistic and MR-Egger was performed with simulation extrapolation
221	(SIMEX) correction for bias adjustment ⁴⁶ . The variance of each trait explained by the genetic
222	instrument (R^2) was estimated and used to perform power calculations ⁴⁷ . F-statistics were
223	also generated. An F-statistic lower than 10 was interpreted as indicative of a weak
224	instrument bias ⁴⁸ . To further assess the robustness of MR estimates, we examined evidence
225	of heterogeneity across individual SNPs using the Cochran Q-statistic, which indicates the
226	presence of invalid instruments (e.g., due to horizontal pleiotropy), if Q is much larger than

its degrees of freedom (No. of instrumental variables minus 1)⁴⁹. MR-PRESSO (Mendelian

228 Randomization Pleiotropy RESidual Sum and Outlier) was used to detect and correct for

229 potential outliers (where Q-statistic p < 0.05)⁵⁰.

230

231 Instrument-risk factor effects

232

233 Where there was evidence for an effect of a metabolic trait on oral or oropharyngeal cancer 234 risk in the primary MR analysis, we conducted further evaluation of the metabolic 235 instruments onto established HNC risk factors using two-sample MR. The largest available 236 GWAS were used for smoking initiation (a binary phenotype indicating whether an 237 individual had ever smoked in their life versus never smokers) (n=21,232,091) and alcoholic 238 drinks per week (defined as the average number of drinks per week aggregated across all 239 types of alcohol, n=2941,280) from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) study ⁵¹. Summary statistics were also obtained from a GWAS of 240 241 general risk tolerance (n=2939,908), derived from a meta-analysis of UK Biobank 242 (n=2431,126) binary question "Would you describe yourself as someone who takes risks?" 243 and the 23andMe (n=2508,782) question "Overall, do you feel comfortable or uncomfortable 244 taking risks?". The GWAS of risk tolerance was based on one's tendency or willingness to take risks, making them more likely to engage in risk-taking behaviours more generally 5^{2} . A 245 246 strong genetic correlation between sexual behaviours and risk tolerance has been shown previously ⁵³. Finally, given the known association between HNC and lower socioeconomic 247 position, we used MR to examine educational attainment (defined by years of schooling)⁵⁴. 248 249 Outcome beta estimates reflect the standard deviation of the phenotype.

250

251 Results

252

253	F-statistics of genetic instruments for metabolic traits ranged from 33.3 – 133.6, indicating
254	sufficient instrument strength for MR analyses (Supplementary Table 1). Genetic
255	instruments were estimated to explain between 0.5% (FI) and 4% (BMI) of their respective
256	metabolic trait (Supplementary Table 1). Based on the results of prior observational studies
257	we would expect to detect OR of >1.10 for a clinically meaningful effect of metabolic traits
258	on oral and oropharyngeal cancer. Supplementary Fig. 1A-C displays power estimates for
259	MR analyses. In analyses where BMI was the exposure, we had 70% power to detect an
260	association with an OR of 1.2 or more at an $lpha$ of 0.05 for combined oral and oropharyngeal
261	cancer. Power was lower for other metabolic traits and reduced when stratifying analyses
262	by subsite (Supplementary Fig. 1).
263	
264	Estimated effect of adiposity on oral and oropharyngeal cancer risk
265	There was limited evidence of an effect of higher BMI or WHR on combined oral and
266	oropharyngeal cancer (OR IVW 0.89, 95%CI 0.72–1.09, p = 0.26, per 1 SD in BMI (4.81 kg/m ²)
267	and OR IVW 0.98, 95%CI 0.74–1.29, p = 0.88, per 1 SD in WHR (0.10 unit)) (Table 1; Fig. 2;
268	Supplementary Fig. 2 & 3). Results were consistent when analyses were stratified by subsite
269	(Table 1). WC, another measure of adiposity did show a protective direction of effect (OR
270	IVW 0.73, 95%Cl 0.52–1.02, p = 0.07, per 1 SD increase in WC (0.09 unit)), particularly in the
271	oropharyngeal subsite (OR IVW 0.66, 95%Cl 0.43–1.01, $p = 0.06$, per 1 SD increase in WC
272	(0.09 unit)) (Table 1; Fig. 2; Supplementary Fig. 4).
273	

274 Estimated effect of glycaemic traits on oral and oropharyngeal cancer risk

275	There was limited evidence for an effect of genetically-proxied T2D on combined oral and
276	oropharyngeal cancer (OR IVW 0.92, 95%Cl 0.84–1.01, p = 0.09, per 1-log unit higher odds of
277	T2D (Table 1; Fig. 2; Supplementary Fig. 5). Traits related to diabetes, including HbA _{1c}
278	resulted in a weak protective effect on combined oral and oropharyngeal cancer risk (OR
279	IVW 0.56, 95%Cl 0.32–1.00, $p = 0.05$, per 1-log-unit % higher HbA _{1c}), which remained only in
280	the oral subsite (OR IVW 0.48, 95%Cl 0.24–0.93, p = 0.03, per 1-log-unit % higher HbA _{1c})
281	following stratification (Table 1; Fig. 2; Supplementary Fig. 6). Conversely, there was limited
282	evidence of an effect for FG (OR IVW 1.06, 95%Cl 0.68–1.66, p = 0.79, per 1-log unit increase
283	in mmol/L fasting glucose) (Table 1; Fig. 2; Supplementary Fig. 7) or FI (OR IVW 0.81, 95%CI
284	0.23–2.89, <i>p</i> = 0.75, per 1-log unit increase in mmol/L fasting insulin) on combined oral and
285	oropharyngeal cancer risk (Table 1; Fig. 2; Supplementary Fig. 8)
285 286	oropharyngeal cancer risk (Table 1; Fig. 2; Supplementary Fig. 8)
	oropharyngeal cancer risk (Table 1; Fig. 2; Supplementary Fig. 8) Estimated effect of increased blood pressure oral and oropharyngeal cancer risk
286	
286 287	Estimated effect of increased blood pressure oral and oropharyngeal cancer risk
286 287 288	Estimated effect of increased blood pressure oral and oropharyngeal cancer risk Finally, there was limited evidence for an effect of SBP on risk of combined oral and
286 287 288 289	Estimated effect of increased blood pressure oral and oropharyngeal cancer risk Finally, there was limited evidence for an effect of SBP on risk of combined oral and oropharyngeal cancer (OR IVW 1.00, 95%CI 0.97–1.03, p = 0.89, per 1 unit mmHg increase in
286 287 288 289 290	Estimated effect of increased blood pressure oral and oropharyngeal cancer risk Finally, there was limited evidence for an effect of SBP on risk of combined oral and oropharyngeal cancer (OR IVW 1.00, 95%CI 0.97–1.03, p = 0.89, per 1 unit mmHg increase in systolic blood pressure) (Table 1; Fig. 2; Supplementary Fig. 9), which did not change when
286 287 288 289 290 291	Estimated effect of increased blood pressure oral and oropharyngeal cancer risk Finally, there was limited evidence for an effect of SBP on risk of combined oral and oropharyngeal cancer (OR IVW 1.00, 95%Cl 0.97–1.03, $p = 0.89$, per 1 unit mmHg increase in systolic blood pressure) (Table 1; Fig. 2; Supplementary Fig. 9), which did not change when stratified by subsite. However, there was some weak evidence for a protective effect of DBP

							Weighted wede					
					IVW		Weighted median		Weighted mode		MR-Egger	
Exposure	Outcome	Exposure/ Outcome source	Outcome N	Number of SNPs	OR (95%CI)	Р	OR (95%Cl)	Р	OR (95%CI)	Р	OR (95%Cl)	Р
	Oral and oropharyngeal cancer combined		6,034	272	0.89 (0.72, 1.09)	0.26	0.71 (0.50, 1.00)	0.05	0.63 (0.37, 1.04)	0.07	0.66 (0.40, 1.10)	0.11
	Oral cancer	Pulit <i>et al.</i> GWAS ³⁰ / GAME-ON ³⁶	2,990	272	0.92 (0.71, 1.19)	0.53	0.83 (0.55, 1.28)	0.40	0.79 (0.38, 1.62)	0.52	0.75 (0.39, 1.41)	0.37
BMI	Oropharyngeal cancer	GAME-ON	2,641	272	0.89 (0.68, 1.15)	0.36	0.75 (0.50, 1.13)	0.17	0.53 (0.27, 1.03)	0.06	0.56 (0.29, 1.07)	0.08
	Oral and oropharyngeal cancer combined		6,034	43	0.73 (0.52, 1.02)	0.07	0.64 (0.40, 1.05)	0.08	0.67 (0.36, 1.26)	0.22	0.43 (0.17, 1.08)	0.08
WC	Oral cancer	Pulit <i>et al.</i> GWAS ³⁰ / GAME-ON ³⁶	2,990	43	0.82 (0.53, 1.26)	0.36	0.66 (0.36, 1.21)	0.18	0.67 (0.32, 1.39)	0.29	0.54 (0.17, 1.76)	0.31
	Oropharyngeal cancer		2,641	43	0.66 (0.43, 1.01)	0.06	0.56 (0.30, 1.05)	0.07	0.37 (0.17, 0.83)	0.02	0.30 (0.09, 0.98)	0.05
	Oral and oropharyngeal cancer combined	_	6,034	176	0.98 (0.74, 1.29)	0.88	0.98 (0.64, 1.49)	0.92	0.95 (0.45, 2.00)	0.89	1.80 (0.87, 3.71)	0.11
WHR	Oral cancer	Shungin <i>et al.</i> GWAS ³¹ / GAME-ON ³⁶	2,990	176	1.18 (0.84, 1.65)	0.35	1.00 (0.58, 1.73)	0.99	0.69 (0.29, 1.67)	0.41	2.49 (1.02, 6.12)	0.05
	Oropharyngeal cancer	GAME-ON	2,641	176	0.83 (0.59, 1.14)	0.25	0.88 (0.51, 1.50)	0.63	0.93 (0.37, 2.30)	0.87	1.19 (0.50, 2.86)	0.70
	Oral and oropharyngeal cancer combined		6,034	254	0.92 (0.84, 1.01)	0.09	0.85 (0.74, 0.97)	0.02	0.84 (0.71, 1.01)	0.06	0.91 (0.77, 1.09)	0.31
	Oral cancer	Uujkovic <i>et al.</i> GWAS ³² / GAME-ON ³⁶	2,990	254	0.94 (0.84, 1.05)	0.27	0.84 (0.72, 0.99)	0.04	0.82 (0.66, 1.02)	0.08	0.88 (0.71, 1.08)	0.22
T2D	Oropharyngea cancer	GAME-ON 30	2,641	254	0.94 (0.84, 1.05)	0.27	0.89 (0.73, 1.10)	0.29	1.02 (0.80, 1.30)	0.88	1.00 (0.81, 1.24)	0.99
HbA _{1c}	Oral and oropharyngeal cancer combined	— Wheeler <i>et al</i> .	6,034	37	0.56 (0.32, 1.00)	0.05	0.52 (0.23, 1.20)	0.12	0.54 (0.24, 1.21)	0.14	0.37 (0.13, 1.05)	0.07
	Oral cancer	GAME-ON ³⁶	2,990	37	0.48 (0.24, 0.93)	0.03	0.51 (0.18, 1.41)	0.19	0.44 (0.15, 1.29)	0.14	0.30 (0.09, 1.03)	0.06
	Oropharyngeal cancer		2,641	37	0.66 (0.31, 1.40)	0.28	0.49 (0.15, 1.57)	0.23	0.57 (0.18, 1.85)	0.35	0.43 (0.11, 1.68)	0.23
	Oral and oropharyngeal		6,034	28	1.06 (0.68, 1.66)	0.79	1.20 (0.62, 2.30)	0.59	1.13 (0.60, 2.12)	0.71	1.11 (0.48, 2.56)	0.80

Table 1. Mendelian randomization results of genetically-proxied metabolic traits with risk of oral and oropharyngeal cancer in GAME-ON

	cancer combined	Lagou <i>et al.</i>										
FG	Oral cancer	GWAS ³³ / GAME-ON ³⁶	2,990	28	1.05 (0.58, 1.92)	0.87	1.15 (0.48, 2.72)	0.75	0.99 (0.44, 2.23)	0.99	1.25 (0.39, 4.01)	0.70
	Oropharyngeal cancer		2,641	28	1.39 (0.77, 2.51)	0.28	1.24 (0.51, 3.03)	0.63	1.36 (0.59, 3.18)	0.48	1.38 (0.45, 4.18)	0.58
	Oral and oropharyngeal cancer combined		6,034	17	0.81 (0.23, 2.89)	0.75	0.75 (0.20, 2.87)	0.68	0.60 (0.03, 10.79)	0.74	0.11 (0.001, 22.47)	0.43
FI	Oral cancer	Lagou <i>et al.</i> GWAS ³³ /	2,990	17	0.96 (0.22, 4.16)	0.96	0.46 (0.08, 2.47)	0.37	0.45 (0.01, 19.02)	0.68	0.21 (0.0004, 107.21	0.63
	Oropharyngeal cancer	GAME-ON 36	2,641	17	0.68 (0.16, 2.87)	0.59	0.66 (0.12, 3.67)	0.63	0.48 (0.05, 4.99)	0.55	0.09 (0.0002, 40.04)	0.45
	Oral and oropharyngeal cancer combined		6,034	83	1.00 (0.97, 1.03)	0.89	0.99 (0.94, 1.03)	0.55	0.98 (0.88, 1.09)	0.66	1.06 (0.92, 1.23)	0.39
SBP	Oral cancer	Evangelou <i>et al.</i> GWAS ³⁵ /	2,990	83	1.01 (0.96, 1.06)	0.74	0.99 (0.93, 1.04)	0.65	0.95 (0.84, 1.08)	0.48	1.09 (0.90, 1.33)	0.37
	Oropharyngeal cancer	GAME-ON ³⁶	2,641	83	0.99 (0.95, 1.03)	0.65	0.99 (0.94, 1.05)	0.77	1.00 (0.88, 1.13)	0.94	1.03 (0.87, 1.23)	0.71
	Oral and oropharyngeal cancer combined		6,034	64	0.93 (0.87, 1.00)	0.05	0.94 (0.86, 1.04)	0.22	1.10 (0.88, 1.38)	0.42	0.99 (0.80, 1.24)	0.95
DBP	Oral cancer	Evangelou <i>et al.</i> GWAS ³⁵ /	2,990	64	0.95 (0.87, 1.04)	0.26	0.96 (0.86, 1.07)	0.45	1.17 (0.88, 1.56)	0.28	0.97 (0.74, 1.27)	0.81
	Oropharyngeal cancer	GAME-ON 36	2,641	64	0.92 (0.84, 1.00)	0.05	0.94 (0.84, 1.05)	0.29	1.10 (0.86, 1.41)	0.45	1.00 (0.75, 1.30)	0.93

296

Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, p-value; BMI, body mass index; WC, waist circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting

glucose; Fl, fasting insulin; HbA_{1c}, glycated haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically predicted BMI (4.81 kg/m²),


299 WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA1c (1-log-unit % higher glycated

300 haemoglobin), SBP (1 unit mmHg increase) and DBP (1 unit mmHg increase).

301 Figure 2. Mendelian randomization results of genetically-proxied metabolic disorders with


302 risk of oral and oropharyngeal cancer including sensitivity analyses in GAME-ON

303



304

305



313 Sensitivity analyses

314

315 We conducted MR Egger, weighted median, and weighted mode analyses in addition to IVW

316 (Table 1; Fig. 2). The results of these analyses generally followed the same pattern as the


317	IVW results reported above, however, there were a number of exceptions. The results for
318	HbA1c were not robust to sensitivity testing (p > 0.05 across methods) (Table 1; Fig. 2). In
319	the analysis of T2D on combined oral and oropharyngeal cancer, the weighted median result
320	provided evidence for a weak protective effect (OR weighted median 0.85, 95%CI 0.74–0.97,
321	p = 0.02). This effect appeared mainly in the oral subsite (OR weighted median 0.84, 95%CI
322	0.72–0.99, $p = 0.04$). Furthermore, in the analysis of WC on oropharyngeal cancer risk, the
323	weighted mode supported IVW result, providing evidence of a protective effect (OR
324	weighted mode 0.37, 95%Cl 0.17–0.83, p = 0.02) (Table 1; Fig. 2).
325	
326	There was clear evidence of heterogeneity in the SNP effect estimates for IVW and MR
327	Egger regression for WHR (Q IVW 213.04, $p = 0.03$; Q MR Egger 209.24, $p = 0.04$), T2D (Q
328	IVW 328.24, p < 0.01; Q MR Egger 328.21, p < 0.01), FI (Q IVW 32.87, p < 0.01; Q MR Egger
329	31.63, <i>p</i> < 0.01) and DBP (Q IVW 95.82 <i>p</i> < 0.01; Q MR Egger 95.22, <i>p</i> < 0.01)
330	(Supplementary Table 2). MR-Egger intercepts were not strongly indicative of directional
331	pleiotropy (Supplementary Table 3), but there were outliers present on visual inspection of
332	scatter plots (Supplementary Figs. 11-19). MR-PRESSO identified 19 outliers for BMI, 2
333	outliers for WC, 12 outliers for WHR, 23 outliers for T2D, 4 outliers for HbA _{1c} , 1 outlier for
334	FG, 3 outliers for FI, 5 outliers for SBP, 7 outliers for DBP (Supplementary Tables 4-5). When
335	correcting for these outliers, this yielded effects consistent with the primary IVW analysis
336	except for adiposity and T2D instruments, which demonstrated a protective effect on
337	combined oral and oropharyngeal cancer risk when outliers were excluded: BMI (OR IVW
338	0.77, 95%Cl 0.62–0.94, <i>p</i> = 0.01, per 1 SD in BMI (4.81 kg/m²)); WC (OR IVW 0.65, 95%Cl
339	0.47–0.89, p = 0.01, per 1 SD in WC (0.09 unit)), and T2D (OR IVW 0.91, 0.84–0.99, p = 0.03,
340	per 1-log unit higher odds of T2D) (Supplementary Table 6). Where there was evidence of

341	violation of the NOME assumption for WC, FI, SBP and DBP (i.e., I ² statistic <0.90)
342	(Supplementary Table 7), MR-Egger was performed with SIMEX correction. SIMEX effects
343	were consistent with the null, except for SBP where an increased risk effect on combined
344	oral and oropharyngeal cancer was found (OR IVW 1.15, 95%Cl 1.05–1.26, <i>p</i> < 0.01, per 1
345	unit mmHg increase in diastolic blood pressure) (Supplementary Table 8).
346	
347	Evaluating instrument-risk factor effects
348	Where there was some evidence for an effect of BMI, WC, WHR , T2D , HbA $_{1c}$ and DBP on
349	oral and oropharyngeal cancer, we carried out further MR analysis to determine causal
350	effects of these metabolic instruments on established risk HNC risk factors. Obesity-related
351	measures showed a strong causal effect on the risk of smoking initiation: BMI (Beta IVW
352	0.21 (standard error (SE) 0.03), p < 0.001, per 1 SD increase in BMI (4.81 kg/m2)), WC (Beta
353	IVW 0.21 (SE 0.05), $p < 0.001$, per 1 SD increase in WC (0.09 unit)) and WHR (Beta IVW 0.18
354	(SE 0.03), <i>p</i> < 0.001, per 1 SD increase in WHR (0.10 unit)) (Supplementary Table 9). There
355	was weaker evidence for an effect of BMI, WC, and genetic liability to T2D on consumption
356	of alcoholic drinks per week: BMI (Beta IVW -0.04 (SE 0.01), <i>p</i> < 0.01, per 1 SD increase in
357	BMI (4.81 kg/m2)), WC (Beta IVW -0.09 (SE 0.02), p < 0.001, per 1 SD increase in WC (0.09
358	unit)) and T2D (Beta IVW -0.02 (SE 0.01), p < 0.001, per 1-log unit higher odds of T2D). BMI
359	(Beta IVW 0.04 (SE 0.01), p <0.001, per 1 SD increase in BMI (4.81 kg/m2)) and WHR (Beta
360	IVW 0.04 (SE 0.02), $p = 0.02$, per 1 SD increase in WHR (0.10 unit)) were also estimated to
361	increase general risk tolerance. Similarly, increased BMI or WHR and genetic liability to T2D
362	were estimated to increase educational attainment (years of schooling): BMI (Beta IVW -
363	0.16 (SE 0.02), <i>p</i> < 0.001, per 1 SD increase in BMI (4.81 kg/m2)), WHR (Beta IVW -0.11 (SE
364	0.02), p < 0.001, per 1 SD increase in WHR (0.10 unit)), and T2D (Beta IVW -0.02 (SE 0.01), p

365	< 0.01, per 1-log unit higher odds of T2D). However, there was strong evidence of both
366	heterogeneity (Supplementary Table 10) and genetic pleiotropy (Supplementary Table 11)
367	across most instrument-risk factor effects. With the exception of alcohol drinks per week,
368	the estimated instrument-risk factor effects remained unchanged following the removal of
369	outlier SNPs detected by MR-PRESSO (Supplementary Table 12).
370	
371	Discussion
372	
373	In this MR study we found limited evidence to support a causal role of genetically-predicted
374	metabolic traits in oral and oropharyngeal cancer, suggesting the risk may have been
375	previously overestimated in observational studies. Where weak evidence for an effect was
376	found (i.e., a protective effect of HbA_{1c}), these results were not robust to sensitivity analysis,
377	including outlier correction. There was also strong evidence for instrument-risk factor
378	effects, suggesting smoking may be a mediator between obesity and HNC.
379	
380	There are several biological mechanisms linking metabolic traits and cancer, but these have
381	not been well explored in HNC $^{55-57}$. Dysregulated metabolism is likely linked to the
382	probability a cancer develops and progresses, given that tumours must adapt to satisfy the
383	bioenergetic and biosynthetic demands of chronic cell proliferation via metabolic
384	reprogramming, enhancing or suppressing the activity of metabolic pathways relative to
385	that in benign tissue ⁵⁸ . In the largest pooled analysis of 17 case-control studies, BMI was
386	associated with a higher risk of overall HNC, but when stratified by subsite the effect was
387	mainly in the larynx (HR 1.42, 95%Cl 1.19–1.70 per 5 2 kg/m ² , p < 0.001) ¹³ . Laryngeal cancer

388	was not included in our study given that GWAS summary data were not available for this
389	subsite and future analysis of this region is therefore warranted. BMI effects on both the
390	oral (HR 1.10, 95%Cl 0.97–1.25, p = 0.14) and oropharyngeal cancer (HR 0.98, 95%Cl 0.84–
391	1.14, $p = 0.77$) subsites were consistent with the effects found in our study (oral cancer OR
392	0.92, 95%Cl 0.71–1.19, $p = 0.53$; oropharyngeal cancer OR 0.89, 0.68–1.15, $p = 0.36$) ¹³ .
393	Conversely, the same pooled analysis found an increased risk for both WC (HR 1.09, 95%CI
394	1.03–1.16, <i>p</i> = 0.006) and WHR (HR 1.17, 95%Cl 1.02–1.34, <i>p</i> = 0.02), mainly in the oral
395	subsite which were not replicated in our MR analysis. Varying patterns of results for these
396	anthropometric measures have been found when stratifying by smoking status within
397	observational studies 13 . The relationship between obesity and HNC is complex. There
398	appears to be a positive association between low BMI (<18.52kg/m ²) and HNC risk, and a
399	protective effect of BMI on HNC risk in current smokers but conversely, a higher risk in
400	never smokers ¹³ . This suggests smoking is a confounder, both as an established risk factor
401	for HNC and in its correlation with weight, with nicotine affecting metabolic energy
402	expenditure, leading to reduced calorie absorption and appetite suppression ⁵⁹ . Instrument-
403	risk factor effect estimates from this study suggest smoking is also a mediator, through
404	which metabolic traits such as BMI influence HNC risk.

405



412	individual components of metabolic syndrome components either, supporting our MR
413	results. While another large meta-analysis found individuals with T2D have an elevated risk
414	of oral cancer ¹⁹ , other more recent studies have found this effect to be mostly in laryngeal
415	subsite (HR 1.25, 95%CI 1.12–1.40) which again we could not investigate in this study ²¹ .
416	Hypertension is the most consistently reported metabolic trait to have an observational
417	association with HNC risk across the subsites $^{21-25}$. We did not identify a clear effect of either
418	SBP or DBP on oral or oropharyngeal cancer using MR, again suggesting the possibility of
419	residual confounding in observational studies.
420	
421	MR was employed in this study in an attempt to overcome the drawbacks of conventional
422	epidemiological studies. However, there are a number of limitations with using this
423	approach and if MR assumptions are violated, this too can generate spurious conclusions.
424	While there was no evidence of weak instrument bias (F statistics > 10), there was
425	heterogeneity present in at least four of the instruments (WHR, T2D, FI and DBP). This is
426	expected to some extent, given that we are instrumenting multiple biological pathways that
427	contribute to complex metabolic phenotypes. The use of multiple related instruments for
428	each metabolic trait may, however, provide some additional confidence in the overall
429	findings. Given the low percentage of variation explained (R^2) for some instruments, as well
430	as the relatively small number of oral and oropharyngeal cancer cases, power to detect an
431	effect may have been an issue in some of our analyses.
432	
433	As with observational studies, there may be issues of measurement error or
434	misclassification in genetic epidemiology, given BMI is simply a function of mass and height

435 and does not specifically measure adiposity. However, BMI has been shown to be an

436	acceptable proxy when used in large samples sizes, correlating with both total body fat 61
437	and total abdominal adipose tissue ⁶² , which is thought to present a greater health risk than
438	fat deposited elsewhere. Furthermore, we used a range of adiposity measures including WC
439	and WHR, which may be better proxies of abdominal adiposity, compared to BMI 63 . SNPs
440	used to proxy these metabolic traits, particularly obesity-related measures BMI, WC and
441	WHR were strongly associated with smoking. Given the heterogeneity of these complex
442	metabolic traits, future work could further examine their pathway specific effects 64 .
443	

444 **Conclusion**

445

446 Overall, there was limited evidence for an effect of genetically-proxied metabolic traits on 447 oral and oropharyngeal cancer risk. These findings suggest metabolic traits may not be 448 effective modifiable risk factors to prioritise as part of future prevention strategies in head 449 and neck cancer. The effect of metabolic traits on the risk of this disease may have been 450 overestimated in previous observational studies, but these cannot be directly compared 451 given the differences in methodological approaches and the interpretation of estimates. 452 Smoking appears to act as a mediator in the relationship between obesity and HNC. 453 Although there is no clear evidence that changing body mass will reduce of increase the risk 454 of HNC directly, dental and medical teams should be aware of the risk of smoking in those 455 who are overweight and therefore the greater risk of cancer when providing smoking 456 cessation and appropriate weight loss advice. 457

458

459 **References**

460

461	1	Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and
-----	---	--

- 462 mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for
- 463 *Clinicians*, doi:<u>https://doi.org/10.3322/caac.21660</u> (2021).
- 464 2 Johnson, D. E. *et al.* Head and neck squamous cell carcinoma. *Nature Reviews* 465 *Disease Primers* 6, 92, doi:10.1038/s41572-020-00224-3 (2020).
- 466 3 Hashibe, M. *et al.* Interaction between Tobacco and Alcohol Use and the Risk of
- 467 Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer
- 468 Epidemiology Consortium. *Cancer Epidem Biomar* 18, 541-550, doi:10.1158/1055-

469 9965.Epi-08-0347 (2009).

- 470 4 Gillison, M. L., Chaturvedi, A. K., Anderson, W. F. & Fakhry, C. Epidemiology of
- 471 Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin

472 *Oncol* **33**, 3235-3242, doi:10.1200/JCO.2015.61.6995 (2015).

- 473 5 World Health Organization (WHO). WHO European Regional Obesity Report 2022.
 474 [Internet] [cited 2022 Jun 06], 2022).
- 475 6 Thomas, S. J., Penfold, C. M., Waylen, A. & Ness, A. R. The changing aetiology of head
- 476 and neck squamous cell cancer: A tale of three cancers? *Clin Otolaryngol* 43, 999-
- 477 1003, doi:10.1111/coa.13144 (2018).

478	7	Conway, D. l.,	Purkayastha, M.,	Chestnutt, I. G.	The changing epidemiology of ora	ıL
-----	---	----------------	------------------	------------------	----------------------------------	----

- 479 cancer: definitions, trends, and risk factors. *British Dental Journal* **225**, 867-873,
- 480 doi:10.1038/sj.bdj.2018.922 (2018).
- 481 8 Carreras-Torres, R. *et al.* Role of obesity in smoking behaviour: Mendelian
- 482 randomisation study in UK Biobank. BMJ (Clinical research ed.) 361, k1767-k1767,
- 483 doi:10.1136/bmj.k1767 (2018).
- 484 9 Carter, A. R. *et al.* Combined Association of Body Mass Index and Alcohol
- 485 Consumption With Biomarkers for Liver Injury and Incidence of Liver Disease: A
- 486 Mendelian Randomization Study. JAMA Network Open 2, e190305-e190305,
- 487 doi:10.1001/jamanetworkopen.2019.0305 (2019).
- 488 10 Carter, A. R. *et al.* Understanding the consequences of education inequality on

489 cardiovascular disease: mendelian randomisation study. BMJ 365, l1855,

- 490 doi:10.1136/bmj.l1855 (2019).
- 491 11 Centers for Disease Control and Prevention. *Obesity and Cancer* [Internet] [cited
- 492 2022 Jun 18],
- 493 https://www.cdc.gov/cancer/obesity/index.htm#:~:text=Being%20overweight%20o
- 494 <u>r%20having%20obesity,the%20United%20States%20each%20year</u>.> (2021).
- 495 12 Davey, R. C. The obesity epidemic: too much food for thought? *British Journal of*
- 496 *Sports Medicine* **38**, 360-363, doi:10.1136/bjsm.2003.007443 (2004).

497	13	Gaudet, M. M. et al. Anthropometry and head and neck cancer:a pooled analysis of
498		cohort data. Int J Epidemiol 44, 673-681, doi: <u>https://dx.doi.org/10.1093/ije/dyv059</u>
499		(2015).
500	14	Jiang, H. et al. The effect of metabolic syndrome on head and neck cancer incidence
501		risk: a population-based prospective cohort study. Cancer & metabolism 9, 25-25,

502 doi:https://dx.doi.org/10.1186/s40170-021-00261-w (2021).

- 503 15 Diaz, Y. *et al.* Body mass index and waist circumference in relation to the risk of 26
- 504 types of cancer: a prospective cohort study of 3.5 million adults in Spain. BMC
- 505 *Medicine* **19**, 10-10, doi:<u>http://dx.doi.org/10.1186/s12916-020-01877-3</u> (2021).
- 506 16 Cao, Z. et al. Association of obesity status and metabolic syndrome with site-specific
- 507 cancers: a population-based cohort study. *Brit J Cancer* **123**, 1336-1344,
- 508 doi:<u>http://dx.doi.org/10.1038/s41416-020-1012-6</u> (2020).
- 509 17 Gribsholt, S. B. *et al.* Hospital-diagnosed overweight and obesity related to cancer
- risk: a 40-year Danish cohort study. *Journal of Internal Medicine* **287**, 435-447,
- 511 doi:<u>http://dx.doi.org/10.1111/joim.13013</u> (2020).
- 512 18 Ward, H. A. *et al.* Measured Adiposity in Relation to Head and Neck Cancer Risk in
- 513 the European Prospective Investigation into Cancer and Nutrition. *Cancer*
- 514 epidemiology, biomarkers & prevention : a publication of the American Association
- 515 for Cancer Research, cosponsored by the American Society of Preventive Oncology
- 516 **26**, 895-904, doi:<u>https://dx.doi.org/10.1158/1055-9965.EPI-16-0886</u> (2017).

- 517 19 Gong, Y., Wei, B., Yu, L. & Pan, W. Type 2 diabetes mellitus and risk of oral cancer
- and precancerous lesions: a meta-analysis of observational studies. *Oral oncology*
- 519 **51**, 332-340, doi:<u>https://dx.doi.org/10.1016/j.oraloncology.2015.01.003</u> (2015).
- 520 20 Saarela, K. *et al.* Cancer incidence among Finnish people with type 2 diabetes during
- 521 1989-2014. *Eur J Epidemiol* **34**, 259-265, doi:<u>https://dx.doi.org/10.1007/s10654-018-</u>
- 522 <u>0438-0</u> (2019).
- 523 21 Kim, H.-B., Kim, G.-J., Han, K.-d. & Joo, Y.-H. Changes in metabolic syndrome status
- and risk of laryngeal cancer: A nationwide cohort study. *PLoS ONE* 16, e0252872-
- 525 e0252872, doi:<u>http://dx.doi.org/10.1371/journal.pone.0252872</u> (2021).
- 526 22 Kim, S.-Y., Han, K.-d. & Joo, Y.-H. Metabolic Syndrome and Incidence of Laryngeal
- 527 Cancer: A Nationwide Cohort Study. *Scientific reports* **9**, 667,
- 528 doi:<u>https://dx.doi.org/10.1038/s41598-018-37061-0</u> (2019).
- 529 23 Stocks, T. *et al.* Blood pressure and risk of cancer incidence and mortality in the
- 530 Metabolic Syndrome and Cancer Project. *Hypertension (Dallas, Tex. : 1979)* **59**, 802-
- 531 810, doi:<u>https://dx.doi.org/10.1161/HYPERTENSIONAHA.111.189258</u> (2012).
- 532 24 Christakoudi, S. *et al.* Blood pressure and risk of cancer in the European Prospective
- 533 Investigation into Cancer and Nutrition. *Int J Cancer* **146**, 2680-2693,
- 534 doi:<u>http://dx.doi.org/10.1002/ijc.32576</u> (2020).
- 535 25 Seo, J.-H., Kim, Y.-D., Park, C.-S., Han, K.-d. & Joo, Y.-H. Hypertension is associated
- with oral, laryngeal, and esophageal cancer: a nationwide population-based study.

537		Scientific reports 10, 10291, doi: <u>https://dx.doi.org/10.1038/s41598-020-67329-3</u>
538		(2020).
539	26	Smith, G. D. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology
540		contribute to understanding environmental determinants of disease? Int J Epidemiol
541		32 , 1-22, doi:10.1093/ije/dyg070 (2003).
542	27	Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal
543		inference in epidemiological studies. <i>Hum Mol Genet</i> 23 , R89-98,
544		doi:10.1093/hmg/ddu328 (2014).
545	28	Sanderson, E. et al. Mendelian randomization. Nature Reviews Methods Primers 2, 6,
546		doi:10.1038/s43586-021-00092-5 (2022).
547	29	Gormley, M. et al. Using genetic variants to evaluate the causal effect of cholesterol
548		lowering on head and neck cancer risk: A Mendelian randomization study. PLOS
549		Genetics 17, e1009525, doi:10.1371/journal.pgen.1009525 (2021).
550	30	Pulit, S. L. et al. Meta-analysis of genome-wide association studies for body fat
551		distribution in 694 649 individuals of European ancestry. <i>Hum Mol Genet</i> 28 , 166-
552		174, doi:10.1093/hmg/ddy327 (2019).
553	31	Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat
554		distribution. <i>Nature</i> 518 , 187-196, doi:10.1038/nature14132 (2015).
555	32	Vujkovic, M. et al. Discovery of 318 new risk loci for type 2 diabetes and related
556		vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis.
557		Nat Genet 52 , 680-691, doi:10.1038/s41588-020-0637-y (2020).

558	33	Lagou, V. et al. Sex-dimorphic genetic effects and novel loci for fasting glucose and
559		insulin variability. Nature Communications 12, 24, doi:10.1038/s41467-020-19366-9
560		(2021).
561	34	Wheeler, E. et al. Impact of common genetic determinants of Hemoglobin A1c on
562		type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic
563		genome-wide meta-analysis. <i>PLoS Med</i> 14, e1002383,
564		doi:10.1371/journal.pmed.1002383 (2017).
565	35	Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci
566		associated with blood pressure traits. <i>Nat Genet</i> 50 , 1412-1425,
567		doi:10.1038/s41588-018-0205-x (2018).
568	36	Lesseur, C. et al. Genome-wide association analyses identify new susceptibility loci
569		for oral cavity and pharyngeal cancer. <i>Nat Genet</i> 48 , 1544-1550,
570		doi:10.1038/ng.3685 (2016).
571	37	Dudding, T. et al. Assessing the causal association between 25-hydroxyvitamin D and
572		the risk of oral and oropharyngeal cancer using Mendelian randomization. Int J
573		<i>Cancer</i> 143 , 1029-1036, doi:10.1002/ijc.31377 (2018).
574	38	Consortium, O. Consortium launches genotyping effort. <i>Cancer Discov</i> 3 , 1321-1322,
575		doi:10.1158/2159-8290.CD-NB2013-159 (2013).
576	39	Pers, T. H., Timshel, P. & Hirschhorn, J. N. SNPsnap: a Web-based tool for
577		identification and annotation of matched SNPs. <i>Bioinformatics</i> 31 , 418-420,
578		doi:10.1093/bioinformatics/btu655 (2014).

579	40	Wald, A.	The Fitting	of Straight Lin	ies if Both Va	ariables are Sub	ject to Error. The
-----	----	----------	-------------	-----------------	----------------	------------------	--------------------

- 580 Annals of Mathematical Statistics **11**, 284-300, 217 (1940).
- 581 41 Hemani, G., Bowden, J. & Smith, G. D. Evaluating the potential role of pleiotropy in
- 582 Mendelian randomization studies. *Hum Mol Genet* **27**, R195-R208,
- 583 doi:10.1093/hmg/ddy163 (2018).
- 584 42 Bowden, J., Smith, G. D., Haycock, P. C. & Burgess, S. Consistent Estimation in
- 585 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
- 586 Estimator. *Genet Epidemiol* **40**, 304-314, doi:10.1002/gepi.21965 (2016).
- 587 43 Hartwig, F. P., Smith, G. D. & Bowden, J. Robust inference in summary data
- 588 Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol
- 589 **46**, 1985-1998, doi:10.1093/ije/dyx102 (2017).
- 590 44 Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
- 591 instruments: effect estimation and bias detection through Egger regression. Int J
- 592 *Epidemiol* **44**, 512-525, doi:10.1093/ije/dyv080 (2015).
- 593 45 Lawlor DA, W. K., Borges MC, Palmer T, Hartwig FP, Hemani G, Bowden JA. . A
- 594 Mendelian Randomization dictionary: Useful definitions and descriptions for
- 595 undertaking, understanding and interpreting Mendelian Randomization studies.
- 596 doi:doi:10.31219/osf.io/6yzs7 (2019).
- 597 46 Bowden, J. *et al.* Assessing the suitability of summary data for two-sample
 598 Mendelian randomization analyses using MR-Egger regression: the role of the I-2
- 599 statistic. Int J Epidemiol **45**, 1961-1974, doi:10.1093/ije/dyw220 (2016).

600 47	Brion.	M. J., Shakhbazov,	. K. & Visscher.	. P. M. Calcula	ing statistical power in
--------	--------	--------------------	------------------	-----------------	--------------------------

- 601 Mendelian randomization studies. Int J Epidemiol 42, 1497-1501,
- 602 doi:10.1093/ije/dyt179 (2013).
- 48 Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian

604 randomization: using genes as instruments for making causal inferences in

605 epidemiology. *Stat Med* **27**, 1133-1163, doi:10.1002/sim.3034 (2008).

- 606 49 Bowden, J. et al. Improving the visualization, interpretation and analysis of two-
- 607 sample summary data Mendelian randomization via the Radial plot and Radial

608 regression. Int J Epidemiol 47, 1264-1278, doi:10.1093/ije/dyy101 (2018).

- 50 Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Publisher Correction: Detection of
- 610 widespread horizontal pleiotropy in causal relationships inferred from Mendelian

611 randomization between complex traits and diseases. *Nat Genet* **50**, 1196,

- 612 doi:10.1038/s41588-018-0164-2 (2018).
- 51 Liu, M. Z. *et al.* Association studies of up to 1.2 million individuals yield new insights

614 into the genetic etiology of tobacco and alcohol use. *Nat Genet* **51**, 237,

615 doi:10.1038/s41588-018-0307-5 (2019).

- 61652Karlsson Linner, R. *et al.* Genome-wide association analyses of risk tolerance and617risky behaviors in over 1 million individuals identify hundreds of loci and shared
- 618 genetic influences. *Nat Genet* **51**, 245-257, doi:10.1038/s41588-018-0309-3 (2019).

- 619 53 Gormley, M. *et al.* Investigating the effect of sexual behaviour on oropharyngeal
- 620 cancer risk: a methodological assessment of Mendelian randomization. *BMC*
- 621 *Medicine* **20**, 40, doi:10.1186/s12916-022-02233-3 (2022).
- 622 54 Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide
- 623 association study of educational attainment in 1.1 million individuals. *Nat Genet* **50**,
- 624 1112-1121, doi:10.1038/s41588-018-0147-3 (2018).
- 625 55 Tseng, K. S., Lin, C., Lin, Y. S. & Weng, S. F. Risk of head and neck cancer in patients
- 626 with diabetes mellitus: a retrospective cohort study in Taiwan. *JAMA Otolaryngol*

627 *Head Neck Surg* **140**, 746-753, doi:10.1001/jamaoto.2014.1258 (2014).

- 628 56 Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? *Nat Rev*629 *Cancer* 4, 891-899, doi:10.1038/nrc1478 (2004).
- 630 57 Grimberg, A. Mechanisms by which IGF-I may promote cancer. *Cancer Biol Ther* 2,
 631 630-635 (2003).
- 632 58 DeNicola, G. M. & Cantley, L. C. Cancer's Fuel Choice: New Flavors for a Picky Eater.
- 633 *Mol Cell* **60**, 514-523, doi:10.1016/j.molcel.2015.10.018 (2015).
- 634 59 Williamson, D. F. *et al.* Smoking Cessation and Severity of Weight Gain in a National
- 635 Cohort. *New Engl J Med* **324**, 739-745, doi:10.1056/nejm199103143241106 (1991).
- 636 60 Esposito, K., Chiodini, P., Colao, A., Lenzi, A. & Giugliano, D. Metabolic syndrome and
- 637 risk of cancer: a systematic review and meta-analysis. *Diabetes care* **35**, 2402-2411,
- 638 doi:10.2337/dc12-0336 (2012).

639	61	Browning, L. M. et al. Measuring abdominal adipose tissue: comparison of simpler			
640		methods with MRI. <i>Obes Facts</i> 4 , 9-15, doi:10.1159/000324546 (2011).			
641	62	Ross, R., Léger, L., Morris, D., de Guise, J. & Guardo, R. Quantification of adipose			
642		tissue by MRI: relationship with anthropometric variables. J Appl Physiol (1985) 72,			
643		787-795, doi:10.1152/jappl.1992.72.2.787 (1992).			
644	63	Lee, C. M., Huxley, R. R., Wildman, R. P. & Woodward, M. Indices of abdominal			
645		obesity are better discriminators of cardiovascular risk factors than BMI: a meta-			
646		analysis. <i>J Clin Epidemiol</i> 61 , 646-653, doi:10.1016/j.jclinepi.2007.08.012 (2008).			
647	64	Udler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations			
648		point to disease mechanisms and subtypes: A soft clustering analysis. PLoS Med 15,			
649		e1002654, doi:10.1371/journal.pmed.1002654 (2018).			
650					
651	Ethics	approval and consent to participate			
652	All stu	dies included as part of the GAME-ON network obtained approval and consent from			
653	their r	espective institutions.			
654					
655	Conse	nt for publication			
656	Not ap	plicable.			
657					
658	Availa	bility of data and materials			
659	Summ	ary-level analysis was conducted using publicly available GWAS data as cited. Full			
660	summa	ary statistics for the GAME-ON outcome data GWAS can be accessed via dbGAP			
661	(OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1, August				

- 662 2017 at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
- 663 <u>bin/study.cgi?study_id=phs001202.v1.p1</u>). There is one selected publication by Lesseur et
- al. related to this data ³⁶. Exposure data is publicly available from the relevant studies and
- via the IEU Open GWAS (<u>https://gwas.mrcieu.ac.uk/</u>). MR analyses were conducted using
- the "TwoSampleMR" package in R (version 3.5.3). A copy of the code and all files used in
- 667 this analysis is available at GitHub
- 668 (https://github.com/MGormley12/metabolic trait hnc mr.git).
- 669

670 Competing interests

- 671 The authors declare that they have no competing interests
- 672

673 Funding

674 M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is

675 currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship.

676 This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z].

For the purpose of open access, the author has applied a CC BY public copyright licence to

678 any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC

679 research fellow at the University of Bristol. J.T. is supported by an Academy of Medical

680 Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust,

681 Global Challenges Research Fund (GCRF), the Government Department of Business, Energy

and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). A.R.N.

- 683 was supported by the National Institute for Health Research (NIHR) Bristol Biomedical
- 684 Research Centre which is funded by the National Institute for Health Research (NIHR) and is
- 685 a partnership between University Hospitals Bristol NHS Foundation Trust and the University

686	of Bristol. Department of Health and Social Care disclaimer: The views expressed are those
687	of the authors and not necessarily those of the NHS, the NIHR or the Department of Health
688	and Social Care. This publication presents data from the Head and Neck 5000 which
689	contributes to international VOYAGER and HEADSpAcE head and neck cancer consortia. The
690	Head and Neck 5000 study was a component of independent research funded by the
691	National Institute for Health Research (NIHR) under its Programme Grants for Applied
692	Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of
693	the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
694	Core funding was also provided through awards from Above and Beyond, University
695	Hospitals Bristol and Weston Research Capability Funding and the NIHR Senior Investigator
696	award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research
697	UK Programme Grant, the Integrative Cancer Epidemiology Programme (C18281/A20919).
698	The VOYAGER study was supported in part by the US National Institute of Dental and
699	Craniofacial Research (NIDCR; R01 DE025712). The genotyping of the HNC cases and
700	controls was performed at the Center for Inherited Disease Research (CIDR) and funded by
701	the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0).
702	E.E.V, C.B. and D.L. are supported by Diabetes UK (17/0005587). E.E.V, and C.B. are
703	supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer
704	Research Fund International grant programme (IIG_2019_2009). M.G., T.D., G.D.S, E.E.V.,
705	R.C.R, and C.B. are part of the Medical Research Council Integrative Epidemiology Unit at
706	the University of Bristol supported by the Medical Research Council (MC_UU_00011/1,
707	MC_UU_00011/5, MC_UU_00011/6, MC_UU_00011/7).
708	

709 Authors' contributions

710	M.G., E.E.V., R.C	.R. and C.B.	conceived	the study	and M.G.	carried	out data	curation and
-----	-------------------	--------------	-----------	-----------	----------	---------	----------	--------------

- analysis. Head and neck cancer summary genetic data was obtained through multiple
- collaborations from studies lead by A.R.N., S.J.T., and M.P. as well as members of VOYAGER
- and HEADSpAcE consortia. The initial manuscript was drafted by M.G., E.E.V. and C.B..
- Expert guidance on MR methodology was provided by T.D., C.B. and G.D.S. All authors M.G.,
- T.D., S.J.T., J.T., A.R.N., M.P., D.L., G.D.S., R.C.R., E.E.V., and C.B. contributed to the
- interpretation of the results and critical revision of the manuscript. All authors read and
- 717 approved the final manuscript. M.G. supervisory team includes R.C.R., E.E.V., J.T., A.R.N and
- 718 G.D.S.